In particular, a statistically significant difference between the SGT and MGPT cohorts was observed concerning gender (males: 3.6% vs. 0.6%); histotype (no special type: 84.4% vs. 71.0%, lobular: 5.2% vs. 14.3%); grading (G1-G2: 50% vs. 56.6%, G3: 42.2% vs. 31.1%); molecular subtype (luminal: 62.7% vs. 77.4%, TNBC: 28.6% vs. 11.2%); ER status (positive: 64.6% vs. 80.0%); family history of BC (positive: 58.8% vs. 66.1%); and family history of OC (positive: 14.6% vs. 7.3%). This evidence concerns the gene ESR1 and breast cancer.